Table of Content

1 Report Overview
1.1 Biosimilars Definition
1.2 Market by Type
1.2.1 Global Biosimilars Market Size Growth Rate by Type, 2018 VS 2024 VS 2034
1.2.2 Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)
1.2.3 Recombinant Glycosylated Proteins
1.3 Market Segment by Application
1.3.1 Global Biosimilars Market Size Growth Rate by Application, 2018 VS 2024 VS 2034
1.3.2 Oncology
1.3.3 Blood Disorders
1.3.4 Growth Hormonal Deficiency
1.3.5 Chronic and Autoimmune Disorders
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Biosimilars Sales
2.1 Global Biosimilars Revenue Estimates and Forecasts 2018-2034
2.2 Global Biosimilars Revenue by Region: 2018 VS 2024 VS 2034
2.3 Global Biosimilars Revenue by Region
2.3.1 Global Biosimilars Revenue by Region (2018-2023)
2.3.2 Global Biosimilars Revenue by Region (2024-2034)
2.4 Global Biosimilars Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Biosimilars Sales Quantity by Region: 2018 VS 2024 VS 2034
2.6 Global Biosimilars Sales Quantity by Region
2.6.1 Global Biosimilars Sales Quantity by Region (2018-2023)
2.6.2 Global Biosimilars Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Biosimilars Sales Quantity by Manufacturers
3.1.1 Global Biosimilars Sales Quantity by Manufacturers (2018-2023)
3.1.2 Global Biosimilars Sales Quantity Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Companies by Biosimilars Sales in 2024
3.2 Global Biosimilars Revenue by Manufacturers
3.2.1 Global Biosimilars Revenue by Manufacturers (2018-2023)
3.2.2 Global Biosimilars Revenue Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Biosimilars Revenue in 2024
3.3 Global Biosimilars Sales Price by Manufacturers
3.4 Global Key Players of Biosimilars, Industry Ranking, 2021 VS 2024
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Biosimilars, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Biosimilars, Product Offered and Application
3.8 Global Key Manufacturers of Biosimilars, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Biosimilars Sales Quantity by Type
4.1.1 Global Biosimilars Historical Sales Quantity by Type (2018-2023)
4.1.2 Global Biosimilars Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Biosimilars Sales Quantity Market Share by Type (2018-2034)
4.2 Global Biosimilars Revenue by Type
4.2.1 Global Biosimilars Historical Revenue by Type (2018-2023)
4.2.2 Global Biosimilars Forecasted Revenue by Type (2024-2034)
4.2.3 Global Biosimilars Revenue Market Share by Type (2018-2034)
4.3 Global Biosimilars Price by Type
4.3.1 Global Biosimilars Price by Type (2018-2023)
4.3.2 Global Biosimilars Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Biosimilars Sales Quantity by Application
5.1.1 Global Biosimilars Historical Sales Quantity by Application (2018-2023)
5.1.2 Global Biosimilars Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Biosimilars Sales Quantity Market Share by Application (2018-2034)
5.2 Global Biosimilars Revenue by Application
5.2.1 Global Biosimilars Historical Revenue by Application (2018-2023)
5.2.2 Global Biosimilars Forecasted Revenue by Application (2024-2034)
5.2.3 Global Biosimilars Revenue Market Share by Application (2018-2034)
5.3 Global Biosimilars Price by Application
5.3.1 Global Biosimilars Price by Application (2018-2023)
5.3.2 Global Biosimilars Price Forecast by Application (2024-2034)
6 North America
6.1 North America Biosimilars Sales by Company
6.1.1 North America Biosimilars Revenue by Company (2018-2023)
6.1.2 North America Biosimilars Sales Quantity by Company (2018-2023)
6.2 North America Biosimilars Market Size by Type
6.2.1 North America Biosimilars Sales Quantity by Type (2018-2034)
6.2.2 North America Biosimilars Revenue by Type (2018-2034)
6.3 North America Biosimilars Market Size by Application
6.3.1 North America Biosimilars Sales Quantity by Application (2018-2034)
6.3.2 North America Biosimilars Revenue by Application (2018-2034)
6.4 North America Biosimilars Market Size by Country
6.4.1 North America Biosimilars Revenue by Country: 2018 VS 2024 VS 2034
6.4.2 North America Biosimilars Revenue by Country (2018-2034)
6.4.3 North America Biosimilars Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Biosimilars Sales by Company
7.1.1 Europe Biosimilars Sales Quantity by Company (2018-2023)
7.1.2 Europe Biosimilars Revenue by Company (2018-2023)
7.2 Europe Biosimilars Market Size by Type
7.2.1 Europe Biosimilars Sales Quantity by Type (2018-2034)
7.2.2 Europe Biosimilars Revenue by Type (2018-2034)
7.3 Europe Biosimilars Market Size by Application
7.3.1 Europe Biosimilars Sales Quantity by Application (2018-2034)
7.3.2 Europe Biosimilars Revenue by Application (2018-2034)
7.4 Europe Biosimilars Market Size by Country
7.4.1 Europe Biosimilars Revenue by Country: 2018 VS 2024 VS 2034
7.4.2 Europe Biosimilars Revenue by Country (2018-2034)
7.4.3 Europe Biosimilars Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Biosimilars Sales by Company
8.1.1 China Biosimilars Sales Quantity by Company (2018-2023)
8.1.2 China Biosimilars Revenue by Company (2018-2023)
8.2 China Biosimilars Market Size by Type
8.2.1 China Biosimilars Sales Quantity by Type (2018-2034)
8.2.2 China Biosimilars Revenue by Type (2018-2034)
8.3 China Biosimilars Market Size by Application
8.3.1 China Biosimilars Sales Quantity by Application (2018-2034)
8.3.2 China Biosimilars Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Biosimilars Sales by Company
9.1.1 APAC Biosimilars Sales Quantity by Company (2018-2023)
9.1.2 APAC Biosimilars Revenue by Company (2018-2023)
9.2 APAC Biosimilars Market Size by Type
9.2.1 APAC Biosimilars Sales Quantity by Type (2018-2034)
9.2.2 APAC Biosimilars Revenue by Type (2018-2034)
9.3 APAC Biosimilars Market Size by Application
9.3.1 APAC Biosimilars Sales Quantity by Application (2018-2034)
9.3.2 APAC Biosimilars Revenue by Application (2018-2034)
9.4 APAC Biosimilars Market Size by Region
9.4.1 APAC Biosimilars Revenue by Region: 2018 VS 2024 VS 2034
9.4.2 APAC Biosimilars Revenue by Region (2018-2034)
9.4.3 APAC Biosimilars Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Biosimilars Sales by Company
10.1.1 Middle East, Africa and Latin America Biosimilars Sales Quantity by Company (2018-2023)
10.1.2 Middle East, Africa and Latin America Biosimilars Revenue by Company (2018-2023)
10.2 Middle East, Africa and Latin America Biosimilars Market Size by Type
10.2.1 Middle East, Africa and Latin America Biosimilars Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Biosimilars Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Biosimilars Market Size by Application
10.3.1 Middle East, Africa and Latin America Biosimilars Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Biosimilars Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Biosimilars Market Size by Country
10.4.1 Middle East, Africa and Latin America Biosimilars Revenue by Country: 2018 VS 2024 VS 2034
10.4.2 Middle East, Africa and Latin America Biosimilars Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Biosimilars Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Pfizer
11.1.1 Pfizer Company Information
11.1.2 Pfizer Overview
11.1.3 Pfizer Biosimilars Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.1.4 Pfizer Biosimilars Products and Services
11.1.5 Pfizer Biosimilars SWOT Analysis
11.1.6 Pfizer Recent Developments
11.2 Novartis
11.2.1 Novartis Company Information
11.2.2 Novartis Overview
11.2.3 Novartis Biosimilars Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.2.4 Novartis Biosimilars Products and Services
11.2.5 Novartis Biosimilars SWOT Analysis
11.2.6 Novartis Recent Developments
11.3 Biocon
11.3.1 Biocon Company Information
11.3.2 Biocon Overview
11.3.3 Biocon Biosimilars Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.3.4 Biocon Biosimilars Products and Services
11.3.5 Biocon Biosimilars SWOT Analysis
11.3.6 Biocon Recent Developments
11.4 Biogen
11.4.1 Biogen Company Information
11.4.2 Biogen Overview
11.4.3 Biogen Biosimilars Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.4.4 Biogen Biosimilars Products and Services
11.4.5 Biogen Biosimilars SWOT Analysis
11.4.6 Biogen Recent Developments
11.5 Fresenius Kabi AG
11.5.1 Fresenius Kabi AG Company Information
11.5.2 Fresenius Kabi AG Overview
11.5.3 Fresenius Kabi AG Biosimilars Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.5.4 Fresenius Kabi AG Biosimilars Products and Services
11.5.5 Fresenius Kabi AG Biosimilars SWOT Analysis
11.5.6 Fresenius Kabi AG Recent Developments
11.6 Boehringer Ingelheim
11.6.1 Boehringer Ingelheim Company Information
11.6.2 Boehringer Ingelheim Overview
11.6.3 Boehringer Ingelheim Biosimilars Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.6.4 Boehringer Ingelheim Biosimilars Products and Services
11.6.5 Boehringer Ingelheim Biosimilars SWOT Analysis
11.6.6 Boehringer Ingelheim Recent Developments
11.7 Merck KgaA
11.7.1 Merck KgaA Company Information
11.7.2 Merck KgaA Overview
11.7.3 Merck KgaA Biosimilars Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.7.4 Merck KgaA Biosimilars Products and Services
11.7.5 Merck KgaA Biosimilars SWOT Analysis
11.7.6 Merck KgaA Recent Developments
11.8 Mylan
11.8.1 Mylan Company Information
11.8.2 Mylan Overview
11.8.3 Mylan Biosimilars Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.8.4 Mylan Biosimilars Products and Services
11.8.5 Mylan Biosimilars SWOT Analysis
11.8.6 Mylan Recent Developments
11.9 Eli Lilly
11.9.1 Eli Lilly Company Information
11.9.2 Eli Lilly Overview
11.9.3 Eli Lilly Biosimilars Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.9.4 Eli Lilly Biosimilars Products and Services
11.9.5 Eli Lilly Biosimilars SWOT Analysis
11.9.6 Eli Lilly Recent Developments
11.10 Teva Pharmaceutical
11.10.1 Teva Pharmaceutical Company Information
11.10.2 Teva Pharmaceutical Overview
11.10.3 Teva Pharmaceutical Biosimilars Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.10.4 Teva Pharmaceutical Biosimilars Products and Services
11.10.5 Teva Pharmaceutical Biosimilars SWOT Analysis
11.10.6 Teva Pharmaceutical Recent Developments
11.11 Dr. Reddy's Laboratories
11.11.1 Dr. Reddy's Laboratories Company Information
11.11.2 Dr. Reddy's Laboratories Overview
11.11.3 Dr. Reddy's Laboratories Biosimilars Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.11.4 Dr. Reddy's Laboratories Biosimilars Products and Services
11.11.5 Dr. Reddy's Laboratories Recent Developments
11.12 Amgen
11.12.1 Amgen Company Information
11.12.2 Amgen Overview
11.12.3 Amgen Biosimilars Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.12.4 Amgen Biosimilars Products and Services
11.12.5 Amgen Recent Developments
11.13 Celltrion
11.13.1 Celltrion Company Information
11.13.2 Celltrion Overview
11.13.3 Celltrion Biosimilars Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.13.4 Celltrion Biosimilars Products and Services
11.13.5 Celltrion Recent Developments
11.14 Samsung Biologics
11.14.1 Samsung Biologics Company Information
11.14.2 Samsung Biologics Overview
11.14.3 Samsung Biologics Biosimilars Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.14.4 Samsung Biologics Biosimilars Products and Services
11.14.5 Samsung Biologics Recent Developments
11.15 Roche
11.15.1 Roche Company Information
11.15.2 Roche Overview
11.15.3 Roche Biosimilars Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.15.4 Roche Biosimilars Products and Services
11.15.5 Roche Recent Developments
11.16 Probiomed
11.16.1 Probiomed Company Information
11.16.2 Probiomed Overview
11.16.3 Probiomed Biosimilars Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.16.4 Probiomed Biosimilars Products and Services
11.16.5 Probiomed Recent Developments
11.17 Apotex
11.17.1 Apotex Company Information
11.17.2 Apotex Overview
11.17.3 Apotex Biosimilars Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.17.4 Apotex Biosimilars Products and Services
11.17.5 Apotex Recent Developments
11.18 Chong Kun Dang
11.18.1 Chong Kun Dang Company Information
11.18.2 Chong Kun Dang Overview
11.18.3 Chong Kun Dang Biosimilars Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.18.4 Chong Kun Dang Biosimilars Products and Services
11.18.5 Chong Kun Dang Recent Developments
11.19 JCR Pharmaceuticals
11.19.1 JCR Pharmaceuticals Company Information
11.19.2 JCR Pharmaceuticals Overview
11.19.3 JCR Pharmaceuticals Biosimilars Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.19.4 JCR Pharmaceuticals Biosimilars Products and Services
11.19.5 JCR Pharmaceuticals Recent Developments
11.20 Gan & Lee Pharmaceuticals
11.20.1 Gan & Lee Pharmaceuticals Company Information
11.20.2 Gan & Lee Pharmaceuticals Overview
11.20.3 Gan & Lee Pharmaceuticals Biosimilars Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.20.4 Gan & Lee Pharmaceuticals Biosimilars Products and Services
11.20.5 Gan & Lee Pharmaceuticals Recent Developments
11.21 Gedeon Richter
11.21.1 Gedeon Richter Company Information
11.21.2 Gedeon Richter Overview
11.21.3 Gedeon Richter Biosimilars Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.21.4 Gedeon Richter Biosimilars Products and Services
11.21.5 Gedeon Richter Recent Developments
11.22 Biocad
11.22.1 Biocad Company Information
11.22.2 Biocad Overview
11.22.3 Biocad Biosimilars Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.22.4 Biocad Biosimilars Products and Services
11.22.5 Biocad Recent Developments
11.23 Coherus Bioscience
11.23.1 Coherus Bioscience Company Information
11.23.2 Coherus Bioscience Overview
11.23.3 Coherus Bioscience Biosimilars Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.23.4 Coherus Bioscience Biosimilars Products and Services
11.23.5 Coherus Bioscience Recent Developments
11.24 Stada Arzneimittel AG
11.24.1 Stada Arzneimittel AG Company Information
11.24.2 Stada Arzneimittel AG Overview
11.24.3 Stada Arzneimittel AG Biosimilars Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.24.4 Stada Arzneimittel AG Biosimilars Products and Services
11.24.5 Stada Arzneimittel AG Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Biosimilars Value Chain Analysis
12.2 Biosimilars Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Biosimilars Production Mode & Process
12.4 Biosimilars Sales and Marketing
12.4.1 Biosimilars Sales Channels
12.4.2 Biosimilars Distributors
12.5 Biosimilars Customers
13 Market Dynamics
13.1 Biosimilars Industry Trends
13.2 Biosimilars Market Drivers
13.3 Biosimilars Market Challenges
13.4 Biosimilars Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Biosimilars Market Size Growth Rate (CAGR) by Type, 2018 VS 2024 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)
Table 3. Major Manufacturers of Recombinant Glycosylated Proteins
Table 4. Global Biosimilars Market Size Growth Rate (CAGR) by Application, 2018 VS 2024 VS 2034 (US$ Million)
Table 5. Global Biosimilars Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 6. Global Biosimilars Revenue by Region (2018-2023) & (US$ Million)
Table 7. Global Biosimilars Revenue Market Share by Region (2018-2023)
Table 8. Global Biosimilars Revenue by Region (2024-2034) & (US$ Million)
Table 9. Global Biosimilars Revenue Market Share by Region (2024-2034)
Table 10. Global Biosimilars Sales Quantity by Region: 2018 VS 2024 VS 2034 (K Units)
Table 11. Global Biosimilars Sales by Region (2018-2023) & (K Units)
Table 12. Global Biosimilars Sales Market Share by Region (2018-2023)
Table 13. Global Biosimilars Sales by Region (2024-2034) & (K Units)
Table 14. Global Biosimilars Sales Market Share by Region (2024-2034)
Table 15. Global Biosimilars Sales Quantity by Manufacturers (2018-2023) & (K Units)
Table 16. Global Biosimilars Sales Quantity Share by Manufacturers (2018-2023)
Table 17. Global Biosimilars Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 18. Global Biosimilars Revenue Share by Manufacturers (2018-2023)
Table 19. Global Biosimilars Price by Manufacturers 2018-2023 (USD/Unit)
Table 20. Global Key Players of Biosimilars, Industry Ranking, 2021 VS 2024
Table 21. Global Biosimilars Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Biosimilars by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Biosimilars as of 2024)
Table 23. Global Key Manufacturers of Biosimilars, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Biosimilars, Product Offered and Application
Table 25. Global Key Manufacturers of Biosimilars, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Biosimilars Sales Quantity by Type (2018-2023) & (K Units)
Table 28. Global Biosimilars Sales Quantity by Type (2024-2034) & (K Units)
Table 29. Global Biosimilars Sales Quantity Share by Type (2018-2023)
Table 30. Global Biosimilars Sales Quantity Share by Type (2024-2034)
Table 31. Global Biosimilars Revenue by Type (2018-2023) & (US$ Million)
Table 32. Global Biosimilars Revenue by Type (2024-2034) & (US$ Million)
Table 33. Global Biosimilars Revenue Share by Type (2018-2023)
Table 34. Global Biosimilars Revenue Share by Type (2024-2034)
Table 35. Biosimilars Price by Type (2018-2023) & (USD/Unit)
Table 36. Global Biosimilars Price Forecast by Type (2024-2034) & (USD/Unit)
Table 37. Global Biosimilars Sales Quantity by Application (2018-2023) & (K Units)
Table 38. Global Biosimilars Sales Quantity by Application (2024-2034) & (K Units)
Table 39. Global Biosimilars Sales Quantity Share by Application (2018-2023)
Table 40. Global Biosimilars Sales Quantity Share by Application (2024-2034)
Table 41. Global Biosimilars Revenue by Application (2018-2023) & (US$ Million)
Table 42. Global Biosimilars Revenue by Application (2024-2034) & (US$ Million)
Table 43. Global Biosimilars Revenue Share by Application (2018-2023)
Table 44. Global Biosimilars Revenue Share by Application (2024-2034)
Table 45. Biosimilars Price by Application (2018-2023) & (USD/Unit)
Table 46. Global Biosimilars Price Forecast by Application (2024-2034) & (USD/Unit)
Table 47. North America Biosimilars Revenue by Company (2018-2023) & (US$ Million)
Table 48. North America Biosimilars Sales Quantity by Company (2018-2023) & (K Units)
Table 49. North America Biosimilars Sales Quantity by Type (2018-2023) & (K Units)
Table 50. North America Biosimilars Sales Quantity by Type (2024-2034) & (K Units)
Table 51. North America Biosimilars Revenue by Type (2018-2023) & (US$ Million)
Table 52. North America Biosimilars Revenue by Type (2024-2034) & (US$ Million)
Table 53. North America Biosimilars Sales Quantity by Application (2018-2023) & (K Units)
Table 54. North America Biosimilars Sales Quantity by Application (2024-2034) & (K Units)
Table 55. North America Biosimilars Revenue by Application (2018-2023) & (US$ Million)
Table 56. North America Biosimilars Revenue by Application (2024-2034) & (US$ Million)
Table 57. North America Biosimilars Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 58. North America Biosimilars Revenue by Country (2018-2023) & (US$ Million)
Table 59. North America Biosimilars Revenue by Country (2024-2034) & (US$ Million)
Table 60. North America Biosimilars Sales Quantity by Country (2018-2023) & (K Units)
Table 61. North America Biosimilars Sales Quantity by Country (2024-2034) & (K Units)
Table 62. Europe Biosimilars Sales Quantity by Company (2018-2023) & (K Units)
Table 63. Europe Biosimilars Revenue by Company (2018-2023) & (US$ Million)
Table 64. Europe Biosimilars Sales Quantity by Type (2018-2023) & (K Units)
Table 65. Europe Biosimilars Sales Quantity by Type (2024-2034) & (K Units)
Table 66. Europe Biosimilars Revenue by Type (2018-2023) & (US$ Million)
Table 67. Europe Biosimilars Revenue by Type (2024-2034) & (US$ Million)
Table 68. Europe Biosimilars Sales Quantity by Application (2018-2023) & (K Units)
Table 69. Europe Biosimilars Sales Quantity by Application (2024-2034) & (K Units)
Table 70. Europe Biosimilars Revenue by Application (2018-2023) & (US$ Million)
Table 71. Europe Biosimilars Revenue by Application (2024-2034) & (US$ Million)
Table 72. Europe Biosimilars Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 73. Europe Biosimilars Revenue by Country (2018-2023) & (US$ Million)
Table 74. Europe Biosimilars Revenue by Country (2024-2034) & (US$ Million)
Table 75. Europe Biosimilars Sales Quantity by Country (2018-2023) & (K Units)
Table 76. Europe Biosimilars Sales Quantity by Country (2024-2034) & (K Units)
Table 77. China Biosimilars Sales Quantity by Company (2018-2023) & (K Units)
Table 78. China Biosimilars Revenue by Company (2018-2023) & (US$ Million)
Table 79. China Biosimilars Sales Quantity by Type (2018-2023) & (K Units)
Table 80. China Biosimilars Sales Quantity by Type (2024-2034) & (K Units)
Table 81. China Biosimilars Revenue by Type (2018-2023) & (US$ Million)
Table 82. China Biosimilars Revenue by Type (2024-2034) & (US$ Million)
Table 83. China Biosimilars Sales Quantity by Application (2018-2023) & (K Units)
Table 84. China Biosimilars Sales Quantity by Application (2024-2034) & (K Units)
Table 85. China Biosimilars Revenue by Application (2018-2023) & (US$ Million)
Table 86. China Biosimilars Revenue by Application (2024-2034) & (US$ Million)
Table 87. APAC Biosimilars Sales Quantity by Company (2018-2023) & (K Units)
Table 88. APAC Biosimilars Revenue by Company (2018-2023) & (US$ Million)
Table 89. APAC Biosimilars Sales Quantity by Type (2018-2023) & (K Units)
Table 90. APAC Biosimilars Sales Quantity by Type (2024-2034) & (K Units)
Table 91. APAC Biosimilars Revenue by Type (2018-2023) & (US$ Million)
Table 92. APAC Biosimilars Revenue by Type (2024-2034) & (US$ Million)
Table 93. APAC Biosimilars Sales Quantity by Application (2018-2023) & (K Units)
Table 94. APAC Biosimilars Sales Quantity by Application (2024-2034) & (K Units)
Table 95. APAC Biosimilars Revenue by Application (2018-2023) & (US$ Million)
Table 96. APAC Biosimilars Revenue by Application (2024-2034) & (US$ Million)
Table 97. APAC Biosimilars Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 98. APAC Biosimilars Revenue by Region (2018-2023) & (US$ Million)
Table 99. APAC Biosimilars Revenue by Region (2024-2034) & (US$ Million)
Table 100. APAC Biosimilars Sales Quantity by Region (2018-2023) & (K Units)
Table 101. APAC Biosimilars Sales Quantity by Region (2024-2034) & (K Units)
Table 102. Middle East, Africa and Latin America Biosimilars Sales Quantity by Company (2018-2023) & (K Units)
Table 103. Middle East, Africa and Latin America Biosimilars Revenue by Company (2018-2023) & (US$ Million)
Table 104. Middle East, Africa and Latin America Biosimilars Sales Quantity by Type (2018-2023) & (K Units)
Table 105. Middle East, Africa and Latin America Biosimilars Sales Quantity by Type (2024-2034) & (K Units)
Table 106. Middle East, Africa and Latin America Biosimilars Revenue by Type (2018-2023) & (US$ Million)
Table 107. Middle East, Africa and Latin America Biosimilars Revenue by Type (2024-2034) & (US$ Million)
Table 108. Middle East, Africa and Latin America Biosimilars Sales Quantity by Application (2018-2023) & (K Units)
Table 109. Middle East, Africa and Latin America Biosimilars Sales Quantity by Application (2024-2034) & (K Units)
Table 110. Middle East, Africa and Latin America Biosimilars Revenue by Application (2018-2023) & (US$ Million)
Table 111. Middle East, Africa and Latin America Biosimilars Revenue by Application (2024-2034) & (US$ Million)
Table 112. Middle East, Africa and Latin America Biosimilars Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 113. Middle East, Africa and Latin America Biosimilars Revenue by Country (2018-2023) & (US$ Million)
Table 114. Middle East, Africa and Latin America Biosimilars Revenue by Country (2024-2034) & (US$ Million)
Table 115. Middle East, Africa and Latin America Biosimilars Sales Quantity by Country (2018-2023) & (K Units)
Table 116. Middle East, Africa and Latin America Biosimilars Sales Quantity by Country (2024-2034) & (K Units)
Table 117. Pfizer Company Information
Table 118. Pfizer Description and Overview
Table 119. Pfizer Biosimilars Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 120. Pfizer Biosimilars Product and Services
Table 121. Pfizer Biosimilars SWOT Analysis
Table 122. Pfizer Recent Developments
Table 123. Novartis Company Information
Table 124. Novartis Description and Overview
Table 125. Novartis Biosimilars Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 126. Novartis Biosimilars Product and Services
Table 127. Novartis Biosimilars SWOT Analysis
Table 128. Novartis Recent Developments
Table 129. Biocon Company Information
Table 130. Biocon Description and Overview
Table 131. Biocon Biosimilars Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 132. Biocon Biosimilars Product and Services
Table 133. Biocon Biosimilars SWOT Analysis
Table 134. Biocon Recent Developments
Table 135. Biogen Company Information
Table 136. Biogen Description and Overview
Table 137. Biogen Biosimilars Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 138. Biogen Biosimilars Product and Services
Table 139. Biogen Biosimilars SWOT Analysis
Table 140. Biogen Recent Developments
Table 141. Fresenius Kabi AG Company Information
Table 142. Fresenius Kabi AG Description and Overview
Table 143. Fresenius Kabi AG Biosimilars Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 144. Fresenius Kabi AG Biosimilars Product and Services
Table 145. Fresenius Kabi AG Biosimilars SWOT Analysis
Table 146. Fresenius Kabi AG Recent Developments
Table 147. Boehringer Ingelheim Company Information
Table 148. Boehringer Ingelheim Description and Overview
Table 149. Boehringer Ingelheim Biosimilars Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 150. Boehringer Ingelheim Biosimilars Product and Services
Table 151. Boehringer Ingelheim Biosimilars SWOT Analysis
Table 152. Boehringer Ingelheim Recent Developments
Table 153. Merck KgaA Company Information
Table 154. Merck KgaA Description and Overview
Table 155. Merck KgaA Biosimilars Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 156. Merck KgaA Biosimilars Product and Services
Table 157. Merck KgaA Biosimilars SWOT Analysis
Table 158. Merck KgaA Recent Developments
Table 159. Mylan Company Information
Table 160. Mylan Description and Overview
Table 161. Mylan Biosimilars Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 162. Mylan Biosimilars Product and Services
Table 163. Mylan Biosimilars SWOT Analysis
Table 164. Mylan Recent Developments
Table 165. Eli Lilly Company Information
Table 166. Eli Lilly Description and Overview
Table 167. Eli Lilly Biosimilars Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 168. Eli Lilly Biosimilars Product and Services
Table 169. Eli Lilly Biosimilars SWOT Analysis
Table 170. Eli Lilly Recent Developments
Table 171. Teva Pharmaceutical Company Information
Table 172. Teva Pharmaceutical Description and Overview
Table 173. Teva Pharmaceutical Biosimilars Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 174. Teva Pharmaceutical Biosimilars Product and Services
Table 175. Teva Pharmaceutical Biosimilars SWOT Analysis
Table 176. Teva Pharmaceutical Recent Developments
Table 177. Dr. Reddy's Laboratories Company Information
Table 178. Dr. Reddy's Laboratories Description and Overview
Table 179. Dr. Reddy's Laboratories Biosimilars Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 180. Dr. Reddy's Laboratories Biosimilars Product and Services
Table 181. Dr. Reddy's Laboratories Recent Developments
Table 182. Amgen Company Information
Table 183. Amgen Description and Overview
Table 184. Amgen Biosimilars Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 185. Amgen Biosimilars Product and Services
Table 186. Amgen Recent Developments
Table 187. Celltrion Company Information
Table 188. Celltrion Description and Overview
Table 189. Celltrion Biosimilars Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 190. Celltrion Biosimilars Product and Services
Table 191. Celltrion Recent Developments
Table 192. Samsung Biologics Company Information
Table 193. Samsung Biologics Description and Overview
Table 194. Samsung Biologics Biosimilars Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 195. Samsung Biologics Biosimilars Product and Services
Table 196. Samsung Biologics Recent Developments
Table 197. Roche Company Information
Table 198. Roche Description and Overview
Table 199. Roche Biosimilars Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 200. Roche Biosimilars Product and Services
Table 201. Roche Recent Developments
Table 202. Probiomed Company Information
Table 203. Probiomed Description and Overview
Table 204. Probiomed Biosimilars Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 205. Probiomed Biosimilars Product and Services
Table 206. Probiomed Recent Developments
Table 207. Apotex Company Information
Table 208. Apotex Description and Overview
Table 209. Apotex Biosimilars Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 210. Apotex Biosimilars Product and Services
Table 211. Apotex Recent Developments
Table 212. Chong Kun Dang Company Information
Table 213. Chong Kun Dang Description and Overview
Table 214. Chong Kun Dang Biosimilars Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 215. Chong Kun Dang Biosimilars Product and Services
Table 216. Chong Kun Dang Recent Developments
Table 217. JCR Pharmaceuticals Company Information
Table 218. JCR Pharmaceuticals Description and Overview
Table 219. JCR Pharmaceuticals Biosimilars Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 220. JCR Pharmaceuticals Biosimilars Product and Services
Table 221. JCR Pharmaceuticals Recent Developments
Table 222. Gan & Lee Pharmaceuticals Company Information
Table 223. Gan & Lee Pharmaceuticals Description and Overview
Table 224. Gan & Lee Pharmaceuticals Biosimilars Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 225. Gan & Lee Pharmaceuticals Biosimilars Product and Services
Table 226. Gan & Lee Pharmaceuticals Recent Developments
Table 227. Gedeon Richter Company Information
Table 228. Gedeon Richter Description and Overview
Table 229. Gedeon Richter Biosimilars Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 230. Gedeon Richter Biosimilars Product and Services
Table 231. Gedeon Richter Recent Developments
Table 232. Biocad Company Information
Table 233. Biocad Description and Overview
Table 234. Biocad Biosimilars Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 235. Biocad Biosimilars Product and Services
Table 236. Biocad Recent Developments
Table 237. Coherus Bioscience Company Information
Table 238. Coherus Bioscience Description and Overview
Table 239. Coherus Bioscience Biosimilars Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 240. Coherus Bioscience Biosimilars Product and Services
Table 241. Coherus Bioscience Recent Developments
Table 242. Stada Arzneimittel AG Company Information
Table 243. Stada Arzneimittel AG Description and Overview
Table 244. Stada Arzneimittel AG Biosimilars Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 245. Stada Arzneimittel AG Biosimilars Product and Services
Table 246. Stada Arzneimittel AG Recent Developments
Table 247. Key Raw Materials Lists
Table 248. Raw Materials Key Suppliers Lists
Table 249. Biosimilars Distributors List
Table 250. Biosimilars Customers List
Table 251. Biosimilars Market Trends
Table 252. Biosimilars Market Drivers
Table 253. Biosimilars Market Challenges
Table 254. Biosimilars Market Restraints
Table 255. Research Programs/Design for This Report
Table 256. Key Data Information from Secondary Sources
Table 257. Key Data Information from Primary Sources
List of Figures
Figure 1. Biosimilars Product Picture
Figure 2. Global Biosimilars Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Figure 3. Global Biosimilars Market Share by Type in 2024 & 2034
Figure 4. Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon) Product Picture
Figure 5. Recombinant Glycosylated Proteins Product Picture
Figure 6. Global Biosimilars Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Figure 7. Global Biosimilars Market Share by Application in 2024 & 2034
Figure 8. Oncology
Figure 9. Blood Disorders
Figure 10. Growth Hormonal Deficiency
Figure 11. Chronic and Autoimmune Disorders
Figure 12. Others
Figure 13. Biosimilars Report Years Considered
Figure 14. Global Biosimilars Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 15. Global Biosimilars Revenue 2018-2034 (US$ Million)
Figure 16. Global Biosimilars Revenue Market Share by Region in Percentage: 2024 Versus 2034
Figure 17. Global Biosimilars Sales Quantity 2018-2034 (K Units)
Figure 18. Global Biosimilars Sales Quantity Market Share by Region (2018-2023)
Figure 19. Global Biosimilars Sales Quantity Market Share by Region (2024-2034)
Figure 20. North America Biosimilars Sales Quantity YoY (2018-2034) & (K Units)
Figure 21. North America Biosimilars Revenue YoY (2018-2034) & (US$ Million)
Figure 22. Europe Biosimilars Sales Quantity YoY (2018-2034) & (K Units)
Figure 23. Europe Biosimilars Revenue YoY (2018-2034) & (US$ Million)
Figure 24. China Biosimilars Sales Quantity YoY (2018-2034) & (K Units)
Figure 25. China Biosimilars Revenue YoY (2018-2034) & (US$ Million)
Figure 26. APAC Biosimilars Sales Quantity YoY (2018-2034) & (K Units)
Figure 27. APAC Biosimilars Revenue YoY (2018-2034) & (US$ Million)
Figure 28. Middle East, Africa and Latin America Biosimilars Sales Quantity YoY (2018-2034) & (K Units)
Figure 29. Middle East, Africa and Latin America Biosimilars Revenue YoY (2018-2034) & (US$ Million)
Figure 30. The Top 10 and Top 5 Players Market Share by Biosimilars Sales Quantity in 2024
Figure 31. The Top 10 and Top 5 Players Market Share by Biosimilars Revenue in 2024
Figure 32. Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2024
Figure 33. Global Biosimilars Sales Quantity Market Share by Type (2018-2034)
Figure 34. Global Biosimilars Revenue Market Share by Type (2018-2034)
Figure 35. Global Biosimilars Sales Quantity Market Share by Application (2018-2034)
Figure 36. Global Biosimilars Revenue Market Share by Application (2018-2034)
Figure 37. North America Biosimilars Revenue Market Share by Company in 2024
Figure 38. North America Biosimilars Sales Quantity Market Share by Company in 2024
Figure 39. North America Biosimilars Sales Quantity Market Share by Type (2018-2034)
Figure 40. North America Biosimilars Revenue Market Share by Type (2018-2034)
Figure 41. North America Biosimilars Sales Quantity Market Share by Application (2018-2034)
Figure 42. North America Biosimilars Revenue Market Share by Application (2018-2034)
Figure 43. North America Biosimilars Revenue Share by Country (2018-2034)
Figure 44. North America Biosimilars Sales Quantity Share by Country (2018-2034)
Figure 45. U.S. Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 46. Canada Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 47. Europe Biosimilars Sales Quantity Market Share by Company in 2024
Figure 48. Europe Biosimilars Revenue Market Share by Company in 2024
Figure 49. Europe Biosimilars Sales Quantity Market Share by Type (2018-2034)
Figure 50. Europe Biosimilars Revenue Market Share by Type (2018-2034)
Figure 51. Europe Biosimilars Sales Quantity Market Share by Application (2018-2034)
Figure 52. Europe Biosimilars Revenue Market Share by Application (2018-2034)
Figure 53. Europe Biosimilars Revenue Share by Country (2018-2034)
Figure 54. Europe Biosimilars Sales Quantity Share by Country (2018-2034)
Figure 55. Germany Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 56. France Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 57. U.K. Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 58. Italy Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 59. Russia Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 60. China Biosimilars Sales Quantity Market Share by Company in 2024
Figure 61. China Biosimilars Revenue Market Share by Company in 2024
Figure 62. China Biosimilars Sales Quantity Market Share by Type (2018-2034)
Figure 63. China Biosimilars Revenue Market Share by Type (2018-2034)
Figure 64. China Biosimilars Sales Quantity Market Share by Application (2018-2034)
Figure 65. China Biosimilars Revenue Market Share by Application (2018-2034)
Figure 66. APAC Biosimilars Sales Quantity Market Share by Company in 2024
Figure 67. APAC Biosimilars Revenue Market Share by Company in 2024
Figure 68. APAC Biosimilars Sales Quantity Market Share by Type (2018-2034)
Figure 69. APAC Biosimilars Revenue Market Share by Type (2018-2034)
Figure 70. APAC Biosimilars Sales Quantity Market Share by Application (2018-2034)
Figure 71. APAC Biosimilars Revenue Market Share by Application (2018-2034)
Figure 72. APAC Biosimilars Revenue Share by Region (2018-2034)
Figure 73. APAC Biosimilars Sales Quantity Share by Region (2018-2034)
Figure 74. Japan Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 75. South Korea Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 76. China Taiwan Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 77. Southeast Asia Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 78. India Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 79. Middle East, Africa and Latin America Biosimilars Sales Quantity Market Share by Company in 2024
Figure 80. Middle East, Africa and Latin America Biosimilars Revenue Market Share by Company in 2024
Figure 81. Middle East, Africa and Latin America Biosimilars Sales Quantity Market Share by Type (2018-2034)
Figure 82. Middle East, Africa and Latin America Biosimilars Revenue Market Share by Type (2018-2034)
Figure 83. Middle East, Africa and Latin America Biosimilars Sales Quantity Market Share by Application (2018-2034)
Figure 84. Middle East, Africa and Latin America Biosimilars Revenue Market Share by Application (2018-2034)
Figure 85. Middle East, Africa and Latin America Biosimilars Sales Quantity Share by Country (2018-2034)
Figure 86. Middle East, Africa and Latin America Biosimilars Revenue Share by Country (2018-2034)
Figure 87. Brazil Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 88. Mexico Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 89. Turkey Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 90. Israel Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 91. GCC Countries Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 92. Biosimilars Value Chain
Figure 93. Biosimilars Production Process
Figure 94. Channels of Distribution (Direct Vs Distribution)
Figure 95. Distributors Profiles
Figure 96. Bottom-up and Top-down Approaches for This Report
Figure 97. Data Triangulation
Figure 98. Key Executives Interviewed